Transitioning from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease (TRAVELESS)
Transitioning from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease (TRAVELESS)
Background and aims: subcutaneous (SC) vedolizumab presents the opportunity for inflammatory bowel disease (IBD) patients to manage their treatment at home. There is currently no data on the process of transitioning patients established on intravenous (IV) to SC as part of routine clinical care. The aim of this programme is to evaluate the clinical and biochemical outcomes of switching a cohort of IBD patients established on IV vedolizumab to SC 12 weeks following the transition.
Methods: 178 adult patients were offered the opportunity to transition to SC vedolizumab. Patients who agreed were reviewed prior to switching and at week 12 (W12) after their first SC dose. Evaluation outcomes included disease activity scores, the IBD-Control patient-reported outcome measures (PROMs) and faecal calprotectin (FCP). Reasons for patients declining or accepting transitioning, pharmacokinetics, adverse drug reactions and risk factors for a poor outcome in SARS-CoV-2 infection were also assessed.
Results: 124 patients agreed to transition, of which 106 patients had been on IV vedolizumab for at least 4 months. There were no statistically significant differences in disease activity scores or IBD-Control PROMs between baseline and W12. A statistically significant increase in FCP was observed (31µg/g vs. 47µg/g; p=0.008), although this was unlikely to be clinically relevant. The most common adverse drug reaction reported was injection site reactions (15%). Based on this cohort of patients, an expected reduction of £572,000 per annum is likely to be achieved.
Conclusions: transitioning patients established on IV vedolizumab to SC appears to be safe and effective, with high patient satisfaction and multiple benefits for the health service.
Ventress, Esther
0d368915-6cad-4379-a64e-881dfadab27e
Young, David
cd51ef07-f80f-48da-930c-f01ccca6d58e
Rahmany, Sohail
9345a4c5-0294-4edf-b8c9-8b88b1627fb7
Harris, Clare
a4bed16a-ae72-4c53-bdcf-40b0c6bbb570
Bettey, Marion
cfd008ff-26e6-450d-a537-13ad34e8e285
Smith, Trevor
53e6838c-2e95-4c8f-9325-53163ab6255d
Moyses, Helen
56434d9c-870f-4539-a66a-c791add44f67
Lech, Magdalena
099a751c-26ce-4a51-821a-567d4204aaf2
Gwiggner, Markus
af72b597-1ead-4155-a25c-0835f7e560c2
Felwick, Richard
b19f1ab6-1de4-4df6-b149-4bc337c3fcb9
Cummings, J R Fraser
d1fea617-b125-4129-89d1-1bfb6d8d2dfe
Ventress, Esther
0d368915-6cad-4379-a64e-881dfadab27e
Young, David
cd51ef07-f80f-48da-930c-f01ccca6d58e
Rahmany, Sohail
9345a4c5-0294-4edf-b8c9-8b88b1627fb7
Harris, Clare
a4bed16a-ae72-4c53-bdcf-40b0c6bbb570
Bettey, Marion
cfd008ff-26e6-450d-a537-13ad34e8e285
Smith, Trevor
53e6838c-2e95-4c8f-9325-53163ab6255d
Moyses, Helen
56434d9c-870f-4539-a66a-c791add44f67
Lech, Magdalena
099a751c-26ce-4a51-821a-567d4204aaf2
Gwiggner, Markus
af72b597-1ead-4155-a25c-0835f7e560c2
Felwick, Richard
b19f1ab6-1de4-4df6-b149-4bc337c3fcb9
Cummings, J R Fraser
d1fea617-b125-4129-89d1-1bfb6d8d2dfe
Ventress, Esther, Young, David, Rahmany, Sohail, Harris, Clare, Bettey, Marion, Smith, Trevor, Moyses, Helen, Lech, Magdalena, Gwiggner, Markus, Felwick, Richard and Cummings, J R Fraser
(2021)
Transitioning from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease (TRAVELESS).
Journal of Crohn's and Colitis.
(doi:10.1093/ecco-jcc/jjab224).
Abstract
Background and aims: subcutaneous (SC) vedolizumab presents the opportunity for inflammatory bowel disease (IBD) patients to manage their treatment at home. There is currently no data on the process of transitioning patients established on intravenous (IV) to SC as part of routine clinical care. The aim of this programme is to evaluate the clinical and biochemical outcomes of switching a cohort of IBD patients established on IV vedolizumab to SC 12 weeks following the transition.
Methods: 178 adult patients were offered the opportunity to transition to SC vedolizumab. Patients who agreed were reviewed prior to switching and at week 12 (W12) after their first SC dose. Evaluation outcomes included disease activity scores, the IBD-Control patient-reported outcome measures (PROMs) and faecal calprotectin (FCP). Reasons for patients declining or accepting transitioning, pharmacokinetics, adverse drug reactions and risk factors for a poor outcome in SARS-CoV-2 infection were also assessed.
Results: 124 patients agreed to transition, of which 106 patients had been on IV vedolizumab for at least 4 months. There were no statistically significant differences in disease activity scores or IBD-Control PROMs between baseline and W12. A statistically significant increase in FCP was observed (31µg/g vs. 47µg/g; p=0.008), although this was unlikely to be clinically relevant. The most common adverse drug reaction reported was injection site reactions (15%). Based on this cohort of patients, an expected reduction of £572,000 per annum is likely to be achieved.
Conclusions: transitioning patients established on IV vedolizumab to SC appears to be safe and effective, with high patient satisfaction and multiple benefits for the health service.
Text
jjab224
- Accepted Manuscript
More information
Accepted/In Press date: 20 December 2021
e-pub ahead of print date: 22 December 2021
Identifiers
Local EPrints ID: 454359
URI: http://eprints.soton.ac.uk/id/eprint/454359
ISSN: 1873-9946
PURE UUID: 08b82e64-7cba-444b-982a-ab30b58cfb2e
Catalogue record
Date deposited: 08 Feb 2022 17:34
Last modified: 17 Mar 2024 07:04
Export record
Altmetrics
Contributors
Author:
Esther Ventress
Author:
David Young
Author:
Sohail Rahmany
Author:
Clare Harris
Author:
Marion Bettey
Author:
Trevor Smith
Author:
Helen Moyses
Author:
Magdalena Lech
Author:
Markus Gwiggner
Author:
Richard Felwick
Author:
J R Fraser Cummings
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics